Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Methylxanthines

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...

Antiasthma Drugs: Muscarinic Receptor Antagonists

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Carbidopa/levodopa products may induce vitamin B6 deficiency and seizures.

The American journal of nursing·2026

Same author

True generic of Flovent HFA inhaler now approved.

The American journal of nursing·2026

Same author

Second drug approved for achondroplasia.

The American journal of nursing·2026

Same author

Updates from the FDA on GLP-1 agonists.

The American journal of nursing·2026

Same author

More warnings about over-the-counter supplements containing hidden drugs.

The American journal of nursing·2026

Same author

Drug for iron deficiency is now approved for pediatric patients.

The American journal of nursing·2026

Search research articles

Related Experiment Video

Updated: Aug 2, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

New Combination Asthma Drug.

Diane S Aschenbrenner¹

¹Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .

The American Journal of Nursing

|April 20, 2023

Summary

A new medication, Airsupra, offers a dual-action approach for acute asthma attacks by combining albuterol and budesonide. Patients using this rescue inhaler should continue their regular asthma maintenance treatments.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Related Experiment Videos

Last Updated: Aug 2, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Acupuncture in a Rat Model of Asthma

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

Area of Science:

Pulmonology
Pharmacology
Respiratory Medicine

Background:

Acute asthma attacks require effective and rapid treatment.
Current rescue inhalers primarily focus on bronchodilation.
The need for anti-inflammatory action during acute exacerbations is recognized.

Purpose of the Study:

To introduce Airsupra, a novel combination inhaler for acute asthma.
To describe the therapeutic mechanism of albuterol and budesonide in this formulation.
To provide guidance on the appropriate use of Airsupra in asthma management.

Main Methods:

Clinical evaluation of a novel combination therapy.
Pharmacological assessment of short-acting beta-agonist and corticosteroid interaction.
Patient counseling on integrated asthma treatment strategies.

Main Results:

Airsupra provides a combined bronchodilator and anti-inflammatory effect for acute asthma.
The drug is intended for rescue use during asthma exacerbations.
Concurrent use with maintenance therapy is advised.

Conclusions:

Airsupra represents a new therapeutic option for managing acute asthma attacks.
The combination addresses both bronchoconstriction and inflammation.
Patients must maintain their prescribed asthma maintenance medications.